Insider Selling: GenMark Diagnostics (GNMK) Insider Sells 4,168 Shares of Stock

GenMark Diagnostics (NASDAQ:GNMK) insider Hany Massarany sold 4,168 shares of the firm’s stock in a transaction on Wednesday, May 23rd. The shares were sold at an average price of $6.88, for a total transaction of $28,675.84. Following the sale, the insider now owns 694,208 shares in the company, valued at approximately $4,776,151.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Hany Massarany also recently made the following trade(s):

  • On Monday, May 21st, Hany Massarany sold 5,459 shares of GenMark Diagnostics stock. The shares were sold at an average price of $6.91, for a total transaction of $37,721.69.
  • On Wednesday, May 2nd, Hany Massarany sold 1,055 shares of GenMark Diagnostics stock. The shares were sold at an average price of $6.18, for a total transaction of $6,519.90.
  • On Monday, February 26th, Hany Massarany sold 17,300 shares of GenMark Diagnostics stock. The shares were sold at an average price of $4.17, for a total transaction of $72,141.00.

GenMark Diagnostics traded up $0.06, hitting $7.00, during midday trading on Thursday, according to MarketBeat Ratings. 526,700 shares of the company traded hands, compared to its average volume of 380,852. The company has a quick ratio of 2.45, a current ratio of 2.79 and a debt-to-equity ratio of 0.24. The company has a market cap of $383.45 million, a price-to-earnings ratio of -5.74 and a beta of 0.55. GenMark Diagnostics has a 52-week low of $3.63 and a 52-week high of $13.50.

GenMark Diagnostics (NASDAQ:GNMK) last posted its quarterly earnings results on Tuesday, May 1st. The medical equipment provider reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. The firm had revenue of $20.65 million for the quarter, compared to the consensus estimate of $17.12 million. GenMark Diagnostics had a negative net margin of 97.90% and a negative return on equity of 77.35%. research analysts forecast that GenMark Diagnostics will post -0.77 EPS for the current year.

GNMK has been the topic of several recent analyst reports. BidaskClub raised shares of GenMark Diagnostics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 24th. Zacks Investment Research raised shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a report on Thursday, January 25th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of GenMark Diagnostics in a report on Tuesday, April 24th. Canaccord Genuity decreased their price objective on shares of GenMark Diagnostics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, February 28th. Finally, BTIG Research set a $11.00 price objective on shares of GenMark Diagnostics and gave the company a “buy” rating in a report on Wednesday, May 2nd. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. GenMark Diagnostics has an average rating of “Buy” and a consensus target price of $10.60.

Several large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its stake in shares of GenMark Diagnostics by 2.8% in the first quarter. JPMorgan Chase & Co. now owns 4,904,257 shares of the medical equipment provider’s stock worth $26,679,000 after buying an additional 131,504 shares in the last quarter. Bellevue Group AG lifted its stake in shares of GenMark Diagnostics by 53.4% in the first quarter. Bellevue Group AG now owns 1,186,502 shares of the medical equipment provider’s stock worth $6,455,000 after buying an additional 412,825 shares in the last quarter. Thrivent Financial for Lutherans lifted its stake in shares of GenMark Diagnostics by 1.3% in the first quarter. Thrivent Financial for Lutherans now owns 596,762 shares of the medical equipment provider’s stock worth $3,246,000 after buying an additional 7,792 shares in the last quarter. Penn Capital Management Co. Inc. lifted its stake in shares of GenMark Diagnostics by 56.4% in the fourth quarter. Penn Capital Management Co. Inc. now owns 543,715 shares of the medical equipment provider’s stock worth $2,267,000 after buying an additional 196,150 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of GenMark Diagnostics by 10.5% in the fourth quarter. Geode Capital Management LLC now owns 508,997 shares of the medical equipment provider’s stock worth $2,122,000 after buying an additional 48,320 shares in the last quarter.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply